HC Wainwright & Co. Reiterates Buy on OKYO Pharma, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on OKYO Pharma and maintained a $7 price target.
October 24, 2024 | 11:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for OKYO Pharma, maintaining a $7 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $7 price target by a reputable analyst suggests a positive outlook for OKYO Pharma, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100